CD4/CD8 double negative mycosis fungoides (MF) is a rare phenotypic variant of this epidermotropic cutaneous T-cell lymphoma. Clinically, this MF form manifests with unusual appearances such as annular lesions confined to one body region as in our patient in whom the lesions were found on the left lower leg. The cellular origin of CD4/CD8 double negative MF is unknown. In our case, the intraepidermal CD4/CD8 double negative clonal T-lymphocytes (CD2+, CD42, CD82, CD302, beta-F1+) expressed programmed death-1 but were negative for CXCL-13 and cytotoxic molecules (TIA-1, granzyme B, perforin). Our observation may give an insight into the histogenesis of this unique MF variant and may also be of therapeutic significance because programmed death-1 may serve as a target for therapeutic intervention. FIGURE 5. A, Intraepidermal and intradermal lymphocytes express beta-F1. B, Lack of expression of CD4 by intraepidermal lymphocytes. C, Intraepidermal lymphocytes are negative for CD8. D, Intraepidermal lymphocytes express PD-1 (immunohistochemistry, original magnification, ·100 A-D).
INTRODUCTION
Mycosis fungoides (MF) is the most common primary cutaneous lymphoma and shows a broad clinicopathologic and prognostic spectrum. 1, 2 CD4/CD8 double negative MF is a rare phenotypic variant. In a recent series, this double negative phenotype has been found in 18 (12%) of 140 patients with early stage MF. 3 Unusual clinical presentations including localized, hypopigmented, and ichthyosiform have been observed to be overrepresented in that cohort. The authors of the original series discussed issues concerning the origin of CD42CD82 neoplastic cells in MF as to whether they could represent a malignant counterpart of the normal subpopulation of lymphocytes or derive from antigen-driven T-cells that lost expression of both markers. 3 Herewith, we describe a patient with MF with this peculiar immunophenotype and demonstrate that the CD42CD82 in our case expressed the programmed death-1 (PD-1), an inhibitory member of the CD28 family located on chromosome 2q37. 4 PD-1 is expressed by a specific subset of T-cells that are normally present in germinal centers with a helper function for follicular B-cells (follicular helper T-cells, T FH cells). These cells are characterized by a unique gene expression profile distinct from those of other naive, memory, and effector T helper subsets. 5 PD-1 expression is a characteristic feature of primary cutaneous CD4-positive small/medium-sized T-cell lymphoma (CD4+ SMPTL) 6 and angioimmunoblastic T-cell lymphoma. 7, 8 We report for the first time the expression of PD-1 in CD4/CD8-double negative MF and discuss its significance.
MATERIALS AND METHODS
Biopsy specimens were fixed in 10% buffered formalin, and sections were routinely processed and embedded in paraffin. Serial 4 micrometer-thick sections were cut for hematoxylin and eosin stains and for immunohistochemical stains. The antibodies used for immunohistochemistry included CD2 (1:50, Novocastra/Leica-Microsystems, Heerbrugg, Switzerland), CD3 (1:75, Dako, Glostrup, Denmark), CD4 (1:2, Novocastra/Leica-Microsystems), CD7 (1:25, Dako, Glostrup), CD8 (1:400, Dako), CD10 (1:100; Novocastra/Leica-Microsystems), CD20 (1:600, Dako), CD30 (1:75; Novocastra/Leica-Microsystems), CD45RO (RTU, Novocastra/Leica-Microsystems), CD45RA (1:100; Novocastra/Leica-Microsystems), CD56 (RTU, Novocastra/Leica-Microsystems), TIA-1 (1:50, Immunotech, Marseille, France), beta F1 (1:50, Thermo Scientific, Germany), T-cell receptor (TCR) gamma/delta (1:100, Thermo Scientific), PD-1 (1:10, developed by G. Roncador, MD, PhD, Madrid, Spain), CXCL-13 (1:10; R&D Systems, Abingdon, United Kingdom), EBER in situ hybridization (RTU, Novocastra/ Leica-Microsystems). Appropriate positive controls were included.
CASE REPORT
A 70-year-old woman presented with long-standing erythematous patches on the left lower leg (Fig. 1 ). The lesions had developed 5 years ago as slightly hypopigmented macular lesions. The annular erythematous margin had appeared 6 months before consultation. Her family history revealed lymphocytic leukemia in a grandchild of the patient. The patient was treated for hypothyroidism but otherwise was healthy. Due to accentuated margins and clinical resemblance to a fungal infection, the patient had been treated with topical antimycotics, with no success. Physical examination did not show enlarged lymph nodes. Results of hematologic examination of peripheral blood, serologic findings lactat dehydrogenase, and radiologic staging including computer tomography of the chest and abdomen did not reveal abnormalities. Patch testing performed in the phase of complete remission did not show delayed type hypersensitivity to standard allergens. After histopathological diagnosis, the patient was treated with Ultraviolet B narrow band (311 nm) (3 times per week) over a period of 10 weeks and topical steroids (mometasone furoate cream, for 5 weeks. This treatment resulted in complete remission. One month after the treatment had been finished, a local relapse with a solitary slightly infiltrated annular lesion on the left lower leg was observed with partially responded to topical steroids (halometasone cream) applied over a period of 3 weeks with partial remission. The patient discontinued treatment because she was afraid of side effects of topical steroids and because she was not disturbed by the disease. Stable disease with a persisting solitary annular lesion was observed during follow-up of 8 months.
Histopathological Findings
The epidermis was slightly acanthotic, with variable degree of spongiosis. Discrete parakeratotic cornification was present (Fig. 2) . The epidermis was heavily infiltrated by small lymphocytes with chromatin dense nuclei, some of them with irregular nuclear contours ( Fig. 3 ). In the upper dermis, the lymphoid infiltrate was mainly arranged around blood vessels, but additionally, a focal interstitial component was present. Eosinophilic granulocytes and plasma cells were not found.
Immunohistochemical Features
Both intraepidermal and intradermal lymphocytes expressed CD2, CD3, and beta-F1, but intraepidermal lymphocytes were negative for CD4 and CD8 ( Figs. 4 and 5) . Approximately, 70% of the intraepidermal lymphocytes expressed CD7. More than 90% of the intraepidermal lymphocytes expressed PD-1, and ,10% showed reactivity for CXCL-13 ( Fig. 5 ). Bcl-6 was expressed by 30% of the intraepidermal lymphocytes. The lymphocytes located in the epidermis were negative for CD45RO, whereas the dermal lymphocytes expressed CD45RO and CD4. CD8 and FOXP3 stained a few dermal lymphocytes, whereas no immunopositivity for the 2 markers was seen in the epidermal component. CD10, CD20, CD30, CD45RA, CD56, and TIA-1, perforin, and granzyme B were not expressed. MUM1 labeled few lymphocytes in both the epidermal and dermal component. Staining for TCR delta chain and in situ hybridization for Epster Barr Virus (EBER) were negative. 
Molecular Biological Assays
TCR rearrangement studies were performed using a multiplex polymerase chain reaction with denaturing gradient gel electrophoresis as described elsewhere 9 and revealed a monoclonal rearrangement of TCR gamma genes.
DISCUSSION
The spectrum of CD4/CD8 double negative cutaneous T-cell lymphomas reported in the literature encompasses MF, pagetoid reticulosis, gamma/delta-positive cutaneous T-cell lymphoma, HTLV-1-associated adult T-cell lymphoma/leukemia, and cases that can be classified as cutaneous peripheral T-cell lymphoma, unspecified according to the WHO classification (2008; 4th edition). [10] [11] [12] [13] [14] [15] Less than 35 cases of CD4/ CD8 double negative early MF have been reported since the first description in 1993 by Ralfkiaer and coworkers 3, [16] [17] [18] [19] Our case supports the observation of Hodak et al that CD4/CD8 double negative MF is often associated with an unusual clinical presentation as in our patient in whom CD4/CD8 double negative MF clinically presented with annular and centrally hypopigmented lesions confined to the left lower leg as 1 body region also referred to as localized MF. Except for the expression of CD30 in early MF, none of the phenotypic MF variants seems to be of prognostic significance. 20 Due to the fact that cases of CD4/CD8 double negative MF had not been recognized before their work, Hodak et al 3 considered the possibility that this variant of MF might be unique to the Middle East. Our patient is of Swiss origin. In conjunction with previous reports, our observation confirms that CD4/CD double negative MF occurs also in countries of central/western Europe. 16, 17, 19 In contrast to the majority of the previously reported cases of CD4/CD8 double negative MF cases, the intraepidermal CD4 and CD8 negative tumor cells in our patient did not express cytotoxic molecules (TIA-1, granzyme B, perforin) indicating that the tumor cells do not belong to cytotoxic T-cells. The classic CD4+ form of MF is considered to represent a neoplasm derived from memory T helper cells. 21 The cellular origin of CD4/CD8 double negative MF, however, is unknown. In our case, the intraepidermal CD4/CD8 double negative clonal lymphocytes expressed PD-1. PD-1 expression in CTCL including MF has been little investigated to date, and the results seem controversial. Roncador et al found PD-1 positivity was found in 4 out of 5 cases (80%). In contrast, Wada et al 8, 22 detected PD-1 immunoreactivity only in 15 of 30 MF cases (50%). In 2 most recent articles, Cetinözman et al 23 reported PD-1 in only a subset of 2 out of 21 MF cases (9%), whereas Kantekure et al 24 detected PD-1 positive T-cells in all 9 patch and plaque MF cases, with 7 of the 9 cases showing .25% of the atypical lymphocytes expressing PD-1. These differences may be due to different antibodies and immunohistochemical protocols and due to different cut-off levels for positivity. There was no specification as to whether these cases manifested the usual and most common CD4+CD8-phenotype.
Expression of PD-1 characterizes follicular helper T-cells (T FH ), which are normally present in germinal centers and possess helper function for B-cells. 4 PD-1 may be expressed on activated T-cells and B-cells. 25, 26 PD-1 is a negative regulator of T-cell activation and proliferation that mediates suppressive action by binding to its ligands PD-L1 and PD-L2. 27 In the context of lymphomas, PD-1 cells have been found to be expressed in nodal angioimmunoblastic T-cell lymphoma and in primary cutaneous lymphomas classified as CD4+ SMPTL and identical lesions diagnosed by others as pseudolymphomatous folliculitis or nodular T-cell pseudolymphoma. 6, 7, 28 It can be speculated that CD4/CD8 double negative MF represents a neoplastic counterpart of T FH cells. Alternatively, expression of PD-1 may be upregulated as the result of activation of antigen-stimulated T-cells with loss of CD4 and CD8 because PD-1 can be expressed on activated T-cells. Remarkably, the PD-1 positive tumor cells in our case did not show expression of CXCL-13 and bcl-6 only in 30%, whereas tumor cells in cutaneous CD4+ SMPTL express both markers. 6 Neoplastic lymphocytes may show a loss of markers expressed by their normal counterparts under physiological conditions. Thus, the lack of expression of CXCL-13 and bcl-6 as markers in our case could argue for the neoplastic nature of the PD-1 positive lymphoid cells. We hypothesize that this CD4/CD8 double negative unusual variant of MF may derive from neoplastic follicular T helper cells.
The CD4/CD8 double negative phenotype in MF seems to have no prognostic significance, as so far reported cases showed an indolent course. 3 This is important as the differential diagnosis includes a heterogeneous group of other CTCL with CD4/CD8 double negative phenotype characterized by an aggressive clinical course. 13 Based on the clinical, histological, and phenotypic findings, cutaneous gamma/delta lymphoma, peripheral T-cell lymphoma, not otherwise specified (NOS), and infiltrates of angioimmunoblastic T-cell lymphoma could be excluded as differential diagnoses in our patient. The absence of eosinophilic granulocytes, the negative patch test, the phenotype of lymphocytes and the detection of clonal T-cells argue against lymphomatoid contact dermatitis.
Although our observation is limited to a single case, it may give an insight into the histogenesis of this MF variant and indicate the direction for future studies in the field. The findings will also be of therapeutic significance because PD-1 may serve as an interesting target for therapeutic intervention. 27 
